Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/c1/6d/67/c16d67ee-75bb-6bc4-4913-bb82f8f0987b/mza_10328428802757500552.jpg/600x600bb.jpg

The Lancet Respiratory Medicine in conversation with

The Lancet Group

57 episodes

2 weeks ago

Dr Finn McQuaid and Dr Matthew Saunders join Arianna Colosio to discuss an analytical framework to describe potential causal relationships between climate change and tuberculosis. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

All content for The Lancet Respiratory Medicine in conversation with is the property of The Lancet Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial

The Lancet Respiratory Medicine in conversation with

18 minutes

4 months ago

Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial

Carole Mitnick & Lorenzo Guglielmetti join Ari Colosio, deputy editor of The Lancet Respiratory Medicine, to discuss the ENDTB-Q trial to evaluate the efficacy and safety of a drug regiment to treat TB in individuals with pre-extensively drug-resistant tuberculosis. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres Continue this conversation on social! Follow us today at... https://thelanc...